关注
Xinyuan Xi
Xinyuan Xi
OB reviewer, FDA
在 fda.hhs.gov 的电子邮件经过验证
标题
引用次数
引用次数
年份
Monocyte metabolic reprogramming promotes pro-inflammatory activity and Staphylococcus aureus biofilm clearance
KJ Yamada, CE Heim, X Xi, KS Attri, D Wang, W Zhang, PK Singh, ...
PLOS Pathogens 16 (3), e1008354, 2020
692020
Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation
Y Tang, H Zhang, X Lu, L Jiang, X Xi, J Liu, J Zhu
Drug delivery 22 (5), 608-618, 2015
462015
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
F Lei, X Xi, SK Batra, TK Bronich
Journal of Pharmacology and Experimental Therapeutics 369 (2), 1, 2019
412019
Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer
F Lei, X Xi, S Rachagani, P Seshacharyulu, GA Talmon, MP Ponnusamy, ...
Journal of Controlled Release, 2020
132020
Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer
X Xi, F Lei, K Gao, J Li, R Liu, AR Karpf, TK Bronich
Journal of Controlled Release 360, 872-887, 2023
62023
Antimicrobial compositions and methods
T Kielian, T Bronich, K Yamada, X Xi
US Patent App. 17/261,074, 2021
2021
Ligand-Installed Polymeric Nanocarriers for Combination Chemotherapy
X Xi
Theses & Dissertations. 467., https://digitalcommons.unmc.edu/etd/467, 2020
2020
系统目前无法执行此操作,请稍后再试。
文章 1–7